Taken with our previous results, these findings demonstrate that axon guidance defects are a key feature of dystroglycanopathy, which arise due to Dystroglycan’s interaction with multiple ECM proteins, secreted axon guidance cues, and transmembrane axon guidance receptors. Here, DAG1 is linked to neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.